Corton Capital Inc. Aldeyra Therapeutics, Inc. Transaction History
Corton Capital Inc.
- $81.2 Million
- Q2 2025
A detailed history of Corton Capital Inc. transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Corton Capital Inc. holds 14,940 shares of ALDX stock, worth $75,596. This represents 0.07% of its overall portfolio holdings.
Number of Shares
14,940Holding current value
$75,596% of portfolio
0.07%Shares
1 transactions
Others Institutions Holding ALDX
# of Institutions
135Shares Held
34.9MCall Options Held
244KPut Options Held
51.6K-
Knoll Capital Management, LLC Miami, FL5.48MShares$27.7 Million14.27% of portfolio
-
Perceptive Advisors LLC New York, NY4.05MShares$20.5 Million0.68% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$18.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.5MShares$17.7 Million0.0% of portfolio
-
Ardsley Advisory Partners LP Stamford, CT2.05MShares$10.4 Million1.29% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $295M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...